Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6 Breast 6 Gastrointestinal 4 Tumor-Agnostic 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Dermatologic 1 CNS 1

Conditions

Interventions

pembrolizumab 26 Specimen Handling 22 Biopsy 22 Magnetic Resonance Spectroscopy 20 Paclitaxel 12 Standard of Care 10 Carboplatin 10 Blood Specimen Collection 10 Bevacizumab 10 atezolizumab 9 Nivolumab 9 Cisplatin 8 Radiosurgery 7 Pemetrexed 7 Capecitabine 7 Surveys and Questionnaires 6 Gemcitabine 6 Cyclophosphamide 6 trastuzumab deruxtecan 5 durvalumab 5 X-Rays 5 Taxes 5 Radiotherapy 5 Irinotecan 5 Fluorouracil 5 olaparib 4 niraparib 4 cabozantinib 4 Oxaliplatin 4 Leucovorin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

patritumab deruxtecan × Tumor-Agnostic × 90 days × Clear all

NCT06941272 2026-05-12

MK-9999-01C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡